Evaluation of Syracuse Healthy Start’s Program for Abnormal Flora Management to Reduce Preterm Birth Among Pregnant Women
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Randomized trials of bacterial vaginosis (BV) treatment among pregnant women to reduce preterm birth have had mixed results. Among non-pregnant women, BV recurs frequently after treatment. Randomized trials of early BV treatment for pregnant women in which recurrence was retreated have shown promise in reducing preterm birth. Syracuse’s Healthy Start (SHS) program began in 1997; in 1998 prenatal care providers for pregnant women living in high infant mortality zip codes were encouraged to screen for abnormal vaginal flora at the first prenatal visit. Vaginal swabs were sent to a referral hospital laboratory for Gram staining and interpretation. SHS encouraged providers to treat and rescreen women with bacterial vaginosis or abnormal flora (BV). We abstracted prenatal and hospital charts of live births between January 2000 and March 2002 for maternal conditions and treatments. We merged abstracted data with local electronic data. We evaluated the effect of BV screening before 22 weeks gestation, treatment, and rescreening using a retrospective cohort study design. Among 838 women first screened before 22 weeks, 346 (41%) had normal flora and 492 (59%) women had BV at a mean of 13 weeks gestation; 202 (24%) did not have treatment documented and 290 (35%) received treatment at a mean of 15 weeks gestation; 267 (92%) of those treated were re-screened. Among pregnant women with early BV, 42 (21%) untreated women and 28 (10%) treated women delivered preterm (Odds Ratio [OR] 0.4, 95% confidence interval [CI] 0.2–0.7)). After adjustment for age, race, prior preterm birth and other possible confounders, treatment remained associated with a reduced risk of preterm birth compared to no treatment (aOR = 0.5, 95% CI 0.3–0.9); the aOR for women with normal flora was not significantly different. Conclusion: Screening, treatment, and rescreening for BV/abnormal flora between the first prenatal visit and 22 weeks gestation showed promise in reducing preterm births and deserves further study.
- Schwebke, J. R., Richey, C. M., & Weiss, H. L. (1999). Correlation of behaviors with microbiological changes in vaginal flora. The Journal of Infectious Diseases, 180, 1632–1636. CrossRef
- Koumans, E. H., Sternberg, M., Bruce, C., McQuillan, G., Kendrick, J., Sutton, M., et al. (2007). The prevalence of bacterial vaginosis in the United States, 2001–2004; Associations with symptoms, sexual behaviors, and reproductive health. Sexually Transmitted Diseases, 34(11), 864–869. CrossRef
- Brotman, R. M., Ravel, J., Cone, R. A., Zenilman, J. M. Vaginal microbiota frequently undergo rapid fluctuations. Presented at the 2009 International Society for STD Research, abstract P4.137, p. 277.
- Riggs, M., Klebanoff, M., Nansel, T., Zhang, J., Schwebke, J., & Andrews, W. (2007). Longitudinal association between hormonal contraceptives and bacterial vaginosis in women of reproductive age. Sexually Transmitted Diseases, 34, 954–959.
- Sobel, J. D., Ferris, D., Schwebke, J., Nyirjesy, P., Wiesenfeld, H. C., Peipert, J., et al. (2006). Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. American Journal of Obstetrics and Gynecology, 194(5), 1283–1289. CrossRef
- Klebanoff, M. A., Hauth, J. C., MacPherson, C. A., Carey, J. C., Heine, R. P., Wapner, R. J., et al. (2004). Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. American Journal of Obstetrics and Gynecology, 190(2), 363–370. CrossRef
- Leitich, H., & Kiss, H. (2007). Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Practice and Research in Clinical Obstetrics and Gynaecology, 21(3), 375–390. CrossRef
- Gotsch, F., Romero, R., Kusanovic, J. P., Mazaki-Tovi, S., Pineles, B. L., Erez, O., et al. (2007). The fetal inflammatory response syndrome. Clinical Obstetrics and Gynecology, 50(3), 652–683. CrossRef
- Cunningham, F. G., Gant, N. F., Leveno, K. J., Gilstrap, L., Hauth, J. C., & Wenstrom, K. D. (2001). Williams obstetrics (21st ed., p. 79). New York: MacGraw-Hill Medical Publishing Division.
- Nygren, P., Fu, R., Freeman, M., Bougatsos, C., Klebanoff, M., Guise, J. M., et al. (2008). Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: An update review for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 148(3), 220–233.
- Ugwumadu, A., Manyonda, I., Reid, F., & Hay, P. (2003). Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: A randomized controlled trial. Lancet, 361, 983–988. CrossRef
- Lamont, R. F., Duncan, S. L. B., Mandal, D., & Bassett, P. (2003). Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstetrica et Gynaecologica, 101, 516–522.
- Larsson, P. G., Fahraeus, L., Carlsson, B., Jakobsson, T., & Forsum, U. (2006). Late miscarriage and preterm birth after treatment with clindamycin: A randomised consent design study according to Zelen. Premature study group of the Southeast Health Care Region of Sweden. BJOG: An International Journal of Obstetrics and Gynaecology, 113(6), 629–637. CrossRef
- Hauth, J. C., Goldenberg, R. L., Andrews, W. W., DuBard, M. B., & Copper, R. L. (1995). Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. New England Journal of Medicine, 333(26), 1732–1736. CrossRef
- Spiegel, C. A., Amsel, R., & Holmes, K. K. (1983). Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. Journal of Clinical Microbiology, 18(1), 170–177.
- Centers for Disease Control and Prevention. (2006). Guidelines for treatment of sexually transmitted diseases. MMWR. Morbidity and Mortality Weekly Report, 47(RR-11), 50–52.
- Goldenberg, R. L., & Rouse, D. J. (1998). Prevention of premature birth. New England Journal of Medicine, 339(5), 313–320. CrossRef
- Lee, S. E., Romreo, R., Jung, H., Park, C. W., Park, J. S., & Yoon, B. H. (2007). The intensity of the fetal inflammatory response in intraamniotic inflammation with and without microbial invasion of the amniotic cavity. American Journal of Obstetrics and Gynecology, 197, 294.e1–294.e6. CrossRef
- Siegel, I., & Gleicher, N. (1981). Development of the fetal immune system. Progress in Clinical and Biological Research, 70, 31–40.
- Hay, P. E., Lamont, R. F., Taylor-Robinson, D., Morgan, D. J., Ison, C., & Pearson, J. (1994). Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. British Medical Journal, 308(6924), 295–298.
- Gratacos, E., Figueras, F., Barranco, M., Vila, J., Cararach, V., Alonso, P. L., et al. (1998). Spontaneous recovery of bacterial vaginosis during pregnancy is not associated with an improved perinatal outcome. Acta Obstetricia et Gynecologica Scandinavica, 77(1), 37–40. CrossRef
- The Coronary Drug Project Research Group. (1980). Influence of adherence and response of cholesterol on mortality in the coronary drug project. The New England Journal of Medicine, 303, 1038–1041. CrossRef
- Evaluation of Syracuse Healthy Start’s Program for Abnormal Flora Management to Reduce Preterm Birth Among Pregnant Women
Maternal and Child Health Journal
Volume 15, Issue 7 , pp 1020-1028
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Premature birth
- Vaginosis, bacterial
- Prenatal care
- Industry Sectors
- Author Affiliations
- 1. Division of STD Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd NE MS E-02, Atlanta, GA, 30333, USA
- 2. Departments of Health and Wellness, Syracuse University, Syracuse, NY, USA
- 3. Center for Maternal and Child Health and Department of Obstetrics and Gynecology, SUNY Upstate Medical University, Syracuse, NY, USA
- 4. The Royal College of Physicians, London, UK
- 5. Syracuse Healthy Start/Case Western University, Cleveland, OH, USA
- 6. Syracuse Healthy Start/Ipas, Chapel Hill, NC, USA